Irland - engelsk - HPRA (Health Products Regulatory Authority)

rowex ltd - rabeprazole sodium - tablets gastro-resistant - 20 milligram - proton pump inhibitors

Irland - engelsk - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rabeprazole sodium - tablets gastro-resistant - 10 milligram - proton pump inhibitors

Irland - engelsk - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rabeprazole sodium - tablets gastro-resistant - 20 milligram - proton pump inhibitors

Irland - engelsk - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - rabeprazole sodium - gastro-resistant tablet - 10 milligram(s) - proton pump inhibitors; rabeprazole - alimentary tract and metabolism, drugs for peptic ulcer and gastro-oesophageal reflux disease (gord), proton pump inhibitors - it is indicated in:
active duodenal ulcer;
active benign gastric ulcer;
symptomatic erosive or ulcerative gastro-oesophageal reflux disease (gord);
gastro-oesophageal reflux disease, long-term management (gord maintenance);
symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic gord)
zollinger-ellison syndrome;
in combination with appropriate antibacterial therapeutic regimens for the eradication of helicobacter pylori in patients with peptic ulcer disease

Irland - engelsk - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - rabeprazole sodium - gastro-resistant tablet - 20 milligram(s) - proton pump inhibitors; rabeprazole - alimentary tract and metabolism, drugs for peptic ulcer and gastro-oesophageal reflux disease (gord), proton pump inhibitors - it is indicated in:
active duodenal ulcer;
active benign gastric ulcer;
symptomatic erosive or ulcerative gastro-oesophageal reflux disease (gord);
gastro-oesophageal reflux disease, long-term management (gord maintenance);
symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic gord)
zollinger-ellison syndrome;
in combination with appropriate antibacterial therapeutic regimens for the eradication of helicobacter pylori in patients with peptic ulcer disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rabeprazole sodium 10mg equivalent to rabeprazole 9.42 mg - enteric coated tablet - 10 mg - active: rabeprazole sodium 10mg equivalent to rabeprazole 9.42 mg excipient: dibutyl sebacate ethylcellulose heavy magnesium oxide   hyprolose hypromellose phthalate iron oxide red magnesium stearate mannitol purified talc titanium dioxide - prolox is indicated for: · treatment and prevention of relapse of gastro-oesophageal reflux disease · symptomatic treatment of gastro-oesophageal reflux disease · treatment of duodenal ulcers · treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rabeprazole sodium 20mg equivalent to rabeprazole 18.85 mg - enteric coated tablet - 20 mg - active: rabeprazole sodium 20mg equivalent to rabeprazole 18.85 mg excipient: dibutyl sebacate ethylcellulose heavy magnesium oxide   hyprolose hypromellose phthalate iron oxide yellow magnesium stearate mannitol purified talc titanium dioxide - prolox is indicated for: · treatment and prevention of relapse of gastro-oesophageal reflux disease · symptomatic treatment of gastro-oesophageal reflux disease · treatment of duodenal ulcers · treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus  pneumoniae , haemophilus influenzae (including β- lactamase-producing strains), moraxella catarrhalis (including β- lactamase-producing strains), or streptococcus pyogenes. cefuroxime axetil tablets, usp are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non- β-lactamase-producing strains only). limitations of use the effectiveness of cefuroxime axetil tablets, usp for sinus infections caused

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - venlafaxine hydrochloride - modified-release tablet - 75mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - venlafaxine hydrochloride - modified-release tablet - 150mg